Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Apr 06 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release detailing two recent approvals from the USFDA for its products. The first approval is for Acetazolamide Tablets USP, which are used to treat glaucoma and altitude sickness, among other conditions. The second approval is for Carbidopa and Levodopa Tablets USP, used to treat symptoms of Parkinson's disease. Both products will be manufactured at Zydus's facilities in India.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 06, 2023, titled "(1) Zydus receives final approval from the USFDA for Acetazolamide Tablets USP, 125 mg and 250 mg and (2) Zydus receives final approval from the USFDA for Carbidopa and Levodopa Tablets USP, 10 mg/100 mg, 25 mg/100 mg, and 25 mg/250 mg ".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases